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Abstract
Background: Over the past 20 years prescription of opioid medicines has markedly increased in 
the UK, despite a lack of supporting evidence for use in commonly occurring, painful conditions. 
Prescribing is often monitored by counting numbers of prescriptions dispensed, but this may not 
provide an accurate picture of clinical practice.
Aim: To use an estimated oral morphine equivalent (OMEQe) dose to describe trends in opioid 
prescribing in non- cancer pain, and explore if opioid burden differed by deprivation status.
Design & setting: A retrospective cohort study using cross- sectional and longitudinal trend analyses 
of opioid prescribing data from Welsh Primary Care General Practices (PCGP) took place. Data were 
used from the Secure Anonymised Information Linkage (SAIL) databank.
Method: An OMEQe measure was developed and used to describe trends in opioid burden over the 
study period. OMEQe burden was stratified by eight drug groups, which was based on usage and 
deprivation.
Results: An estimated 643 436 843 milligrams (mg) OMEQe was issued during the study. Annual 
number of prescriptions increased 44% between 2005 and 2015, while total daily OMEQe per 1000 
population increased by 95%. The most deprived areas of Wales had 100 711 696 mg more OMEQe 
prescribed than the least deprived over the study period.
Conclusion: Over the study period, OMEQe burden nearly doubled, with disproportionate OMEQe 
prescribed in the most deprived communities. Using OMEQe provides an alternative measure of 
prescribing and allows easier comparison of the contribution different drugs make to the overall 
opioid burden.
Davies E et al. BJGP Open 2020; DOI: 10.3399/bjgpopen20X101122
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How this fits in
It is known that opioid prescribing has increased in the UK over the past 20 years. Measures of 
prescribing vary and are not always reflective of what is seen in practice, nor do they allow easy 
identification of populations or individuals most at risk. This study used an OMEQe to standardise 
prescribing data. It demonstrated anomalies in prescription numbers and opioid burden. The use 
of OMEQ provides more easily comparable data across a range of opioid medicines and warrants 
consideration as a standard measure of prescribing.
Introduction
The number of prescriptions for opioid medicines issued in the UK has increased substantially over 
the past 20 years.1–6 In particular, prescriptions for ‘strong’ opioids, such as morphine, oxycodone, 
and fentanyl, have seen greater increases than those classed as ‘weak’, such as codeine and 
dihydrocodeine.1,2,6 Prescribing continued to increase even when evidence to support using these 
medicines for people living with non- cancer pain is largely absent.7–11
National and international concerns have focused on strong opioids.12–14 However, dose and 
duration of use are more likely indicators of harm or potential for dependence than the choice of 
drug itself.11,15–20 It has been estimated that adverse events occur in as many as 78% of people using 
opioids over extended periods of time.11–13 Higher doses14–17 have been associated with depression 
and anxiety,18–20 and an increased risk of dependence and misuse.21–24 It has been proposed the 
burden or risk of opioids would be more accurately discussed in mg doses or dose equivalents, rather 
than number of prescriptions alone.2,25
An accurate estimation of opioid burden and risk is especially important in areas of high 
socioeconomic deprivation, which are associated with poorer health outcomes, higher incidence of 
chronic pain,2,26,27 and mental health disorders compared with the general population.28 Deprivation is 
associated with higher prescribing of potentially dependence- forming medicines, including opioids, 
especially for chronic, non- cancer pain in the UK29 and internationally.30 Furthermore, concomitant 
use of other medicines, such as benzodiazepines and antidepressants with opioids, have also been 
disproportionately reported in more deprived areas and confer additional risk of harm to the user.31–33
Wales has historically high levels of deprivation.34 In 2016, 23% of the Welsh population lived 
in poverty, more than in England (22%), Scotland (19%), or Northern Ireland (20%).35 The south of 
the country contains the majority of the most deprived areas in Wales,36 and also has the highest 
opioid- related death rates in England and Wales.29 However, only one comprehensive analysis of 
Welsh opioid prescribing has been undertaken.4
The aim of this study was to examine opioid prescribing trends in Wales between 2005 and 
2015 using an estimated measure of daily OMEQ dose to standardise data. Analysis of OMEQe by 
deprivation quintile determined if opioid burden varied in distinct areas of socioeconomic deprivation.
Method
Data source
The study used individuals' anonymised data held in the SAIL databank, which is part of the national 
e- health records research infrastructure for Wales.37,38
Each individual was allocated a unique anonymised linkage field (ALF) number. The ALF allowed 
cross- linking between different existing datasets, providing a record of all healthcare interactions for 
each individual whose data is available to SAIL. A dataset was produced by cross- linking individuals’ 
anonymised records from the PCGP and Welsh Index of Multiple Deprivation (WIMD) 2011 datasets, 
based on the local super output areas (LSOAs) contained within the PCGP dataset.
At the time of this study, the databank contained complete data from 1 January 2005–31 December 
2015 and so 11 years of available data were examined.
Opioid prescriptions
Prescriptions are automatically assigned Read codes on the electronic patient record, when issued in 
primary care, providing consistent identification of data.1,3,37,38 Read codes are a thesaurus of clinical 
terms used to record interactions, diagnoses, and interventions in primary care settings in Wales. A 
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list of Read codes was compiled for all prescribable oral and transdermal opioid medicines used for 
analgesia, including combination products, for example, paracetamol and codeine (co- codamol), using 
the NHS Information Authority’s clinical terminology browser. Products licensed for the management 
of misuse and injectable opioids, which are reserved for palliative care, were excluded.
Only data for people aged ≥18 years between 2005 and 2015 without a recorded cancer diagnosis 
(identified using Read codes for cancer diagnoses or treatment) at any time between 2004 and 2015 
were included in the analysis.
All data were subjected to repeated cross- sectional sampling to determine prescribing trends over 
the study period.
Estimated oral morphine equivalent dose
At the time of this study, dispensing data were not included within SAIL datasets. The prescribed drug 
product, including strength, was available from PCGP data, but not administration directions and 
quantity of each opioid product prescribed. Therefore, actual oral morphine equivalent dose for each 
individual could not be calculated.
An OMEQe measure was developed using data available from SAIL (Table 1). For each product, 
the recommended daily dose per day was taken from the British National Formulary39 and electronic 
medicines compendium (emc).40 The daily dose was converted to a daily OMEQe value, based on 
available conversion tables.8,39 Daily OMEQe for each product was multiplied by the number of 
prescriptions issued each year to determine annual totals (Table 1). Results were stratified by drug, 
with less frequently prescribed medicines (oral diamorphine, dipipanone, hydromorphone, meptazinol, 
methadone tablets, pentazocine, pethidine, and tapentadol) grouped as ‘other’ opioids.
Measuring utilisation
The number of prescriptions and number of patients per year were calculated per drug in repeat 
cross- sections for each year and further stratified by deprivation quintile. Data were standardised to 
annual population size for the SAIL databank, using data from the Office for National Statistics (ONS)41 
and StatsWales.42 Deprivation data were adjusted by each quintile’s annual population.42
Data analysis
Data were extracted from the study tables within SAIL using Structured Query Language (SQL) 
code. Percentage change rate of number of prescriptions issued and number of people receiving 
prescriptions over the study period were also noted. Data were stratified into eight drug groups.
Shapiro- Wilk calculations showed data were non- parametric. Therefore, Kruskal- Wallis tests were 
used to examine differences in mean prescribing over the study period in the different drug groups 
and deprivation quintiles. Statistical analysis was conducted using IBM SPSS Statistics software (version 
25.0) and figures drawn using Excel (version 16.30; retrieved from https:// office. microsoft. com/ excel).
Deprivation scores
The WIMD is the official measure used by Welsh Government to determine relative deprivation of 
areas within Wales.36 The WIMD is a weighted total score of deprivation based on income (23.5%), 
employment (23.5%), health (14%), education (14%), geographical access of services (10%), community 
safety (5%), physical environment (5%), and housing (5%). Scores are not linear, so areas in group two 
are not twice as deprived as those in group four. Indices are published every 3 years.43 The 2011 index 
was recommended by SAIL for use in this study, as representative of the full 11- year period. There 
were no significant changes in LSOA or WIMD areas in that time. Data are presented in quintiles, with 
WIMD1 being the most deprived areas and WIMD5 the least deprived.
Results
Prescribing data were extracted from 345 PCGPs across Wales. A total of 22 641 424 prescriptions 
for opioids were included in the analysis. Between 2005 and 2015, opioid prescriptions increased 
by 44% from 692 to 994 prescriptions per 1000 population annually. The total daily OMEQe, issued 
from all included practices in Wales, more than doubled in the 11 years examined, from 37 662 651 
Davies E et al. BJGP Open 2020; DOI: 10.3399/bjgpopen20X101122
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Table 1 Example of calculations for OMEQe (mg) using 2005 data for female subjects
Units used for calculating annualised OMEQe
Drug product Recommended daily dosea,b Oral morphine equivalent of 
daily dose (mg)c,d
Annual number of 
prescriptions
Annualised total OMEQe 
burden (mg)
Buprenorphine
10 mcg per hour 1 patch per week 24 28 672
52.5 mcg per hour 1 patch twice a week 126 354 44 604
Codeine
Co- codamol 8/500 2 tablets 4 times a day 6.4 17 952 114 893
Codeine phosphate 30 mg 2 tablets 4 times a day 24 16 293 391 032
Zapain capsules (30/500) 2 tablets 4 times a day 24 112 2688
Dihydrocodeine
Co- dydramol 10/500 2 tablets 4 times a day 8 153 047 1 224 376
DHC Continus 90 mg MR 
tablet
1 tablet twice a day 18 1009 18 612
Remedeine tablet 2 tablets 4 times a day 16 1295 20 720
Fentanyl
Durogesic 100 mcg per hour 
patch
1 patch every 3 days 360 131 47 160
Fentanyl 200 mcg SL lozenge 1 lozenge 4 times a day 120 40 4800
Fentanyl 25 mcg per hour 
patch
1 patch every 3 days 90 3429 308 610
Morphine
Morphgesic SR 10 mg m/r 
tablet
1 tablet twice a day 20 73 730
MXL 60 mg m/r capsule 1 capsule once a day 60 23 1380
Oramorph 10 mg/5 ml liquid 
100 ml
5 mL every 2 hours 120 573 68 760
Sevredol 20 mg tablet 1 tablet every 6 hours 120 299 35 880
Oxycodone
Longtec 20 mg m/r tablets 1 tablet twice a day 80 1 80
Oxycodone HCl 20 mg 
capsule
1 capsule every 4 hours 240 250 60 000
OxyContin 80 mg m/r tablet 1 capsule twice a day 320 262 83 840
Tramadol
Dromadol XL 200 mg m/r 
tablet
1 tablet once daily 20 11 220
Tramadol 50 mg capsule 2 capsules 4 times a day 40 93 918 3 756 720
Tramacet 325 mg/37.5 mg 2 tablets 4 times a day 30 4450 133 500
Other
Co- proxamol 32.5 mg/325 mg 
tablet
2 tablets 4 times a day 26 82 015 2 132 390
Hydromorphone HCl 1.3 mg 
capsule
1 capsule every 4 hours 58.5 6 351
Pethidine HCl 50 mg tablet 1 tablet every 4 hours 30 2381 71 430
Annualised total = estimated oral morphine equivalent of daily dose x annual number of prescriptions. Process repeated for each drug product and 
totalled for each year. a39 b40 c8 d64 OMEQe = estimated oral morphine equivalent.
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Table 2 Daily OMEQe (mg) issued on prescription, given as annual totals and adjusted to population, 
stratified by drug
Oral or transdermal opioids
Total daily OMEQe 
(mg) dose prescribed
Annual total daily 
OMEQe dose 
(mg) per 1000 
population
OMEQe dose (mg) 
per prescription 
issued
Annual number of 
prescriptions issued 
per 1000 population
Buprenorphine 23 641 528
2005 977 464 422 98 4
2015 2 756 458 1142 37 31
Rate change, % 182 170.5 –61.7 606.3
Codeine 223 817 156
2005 13 743 115 5916 17 357
2015 25 593 382 10 581 19 549
Rate change, % 86.2 78.8 16.2 53.9
Dihydrocodeine 44 600 874
2005 4 368 806 1887 12 154
2015 3 471 460 1438 13 109
Rate change, % –20.5 –23.8 7.7 –29.2
Fentanyl 64 138 905
2005 2 695 290 1164 186 6
2015 6 496 270 2691 147 18
Rate change, % 141.0 131.2 –21.2 193.2
Morphine 91 132 530
2005 3 293 220 1422 86 17
2015 17 047 800 7063 68 104
Rate change, % 417.7 396.6 –20.6 525.6
Oxycodone 45 120 680
2005 1 316 480 569 105 5
2015 6 165 400 2554 100 26
Rate change, % 368.3 349.3 –4.9 372.4
Tramadol 144 173 635
2005 7 865 695 3397 36 95
2015 14 252 335 5905 38 156
Rate change, % 81.2 73.8 5.7 64.4
Other 8 888 696
2005 3 446 735 1719 27 56
2015 699 711 347 58 5
Rate change, % –79.7 –79.8 117.4 –91.0
Results are rounded to nearest whole number. Rate change (%) calculated using original, unrounded data. 
Original data are available from the authors on request.
Davies E et al. BJGP Open 2020; DOI: 10.3399/bjgpopen20X101122
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mg to 76 428 768 mg. When adjusted to population, annualised daily OMEQe per 1000 population 
increased by 95% (from 16 266 mg to 31 665 mg) over the study period (Table 1).
Total estimated oral morphine equivalent prescribed
Codeine was the most commonly prescribed opioid (Table 2), with just under 12.5 million prescriptions 
issued and the highest annual total OMEQe prescribed for the study duration (Figure 1). Codeine 
OMEQe per 1000 population increased by 79%, from 5916 mg to 10 581 mg. Tramadol was the 
second most commonly prescribed opioid in Wales with a 74% increase, from 3397 mg to 5905 mg 
OMEQe per 1000 population, although annual total OMEQe started to reduce from 2014 (Figure 2).
Large increases were noted in ‘strong’ opioids (morphine, oxycodone, fentanyl, and buprenorphine) 
during the study (Figure 2). Morphine OMEQe increased by 397%, from 1422 mg to 7063 mg per 
1000 population (Table 2). By 2015, morphine was prescribed at three times the equivalent dose 
of either oxycodone (increased 349%, from 569 mg to 2554 mg per 1000 population) or fentanyl 
(increased 131%, from 1164 mg to 2691 mg per 1000 population).
Overall, 71% of the total opioid burden in the areas of Wales covered by the SAIL databank was 
accounted for by three drugs: codeine (35%), tramadol (22%), and morphine (14%). Statistically 
significant differences were found between the 11- year total OMEQe when each drug group was 
compared with the others (P<0.001, H = 73.5, ฦ2 = 0.8).
Figure 1 Comparison of the percentage contribution of each opioid prescribed by total prescriptions issued and total daily OMEQe dose (mg) in Wales 
between 2005 and 2015
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Opioid prescribing trends by deprivation
Figure 3 illustrates the trends in annualised daily OMEQe of all oral and transdermal opioids stratified 
by the WIMD (2011). Over the study, people in the most deprived quintiles (WIMD1) were prescribed 
an estimated 100 711 696 mg more OMEQe than in the least deprived (WIMD5) (Table 3).
Between 2005 and 2015, OMEQe doubled in all but the least deprived (WIMD5) areas (Table 3). 
Twenty- eight per cent (176 824 265 mg of 622 969 068 mg) of total OMEQe was issued in the most 
deprived areas of Wales. In contrast, 12% (76 112 569 mg) were prescribed in the least deprived areas. 
Throughout the study, OMEQe prescribed in WIMD1 areas remained more than twice those noted in 
WIMD5 areas (Table 3) for both total OMEQe (mg) and OMEQe per 1000 population. Despite large 
percentage increases in all quintiles, the difference between total OMEQe prescribed per quintile 
were statistically significant (P<0.001, H = 34.5, ฦ2 = 0.61).
Discussion
Summary
This study identified trends in opioid prescribing in Wales, similar to those previously reported in other 
parts of the UK.1,3,6,26,27,44 A marked increase in opioid burden in Wales between 2005 and 2015 was 
noted. Using the OMEQe measure described, opioid burden in the study population nearly doubled 
in 11 years. Increasing deprivation was associated with higher OMEQe and, consequently, a higher 
burden per person, despite rises in percentage terms being similar in all WIMD 2011 quintiles.
Figure 2 Trends in opioid prescribing across Wales, 2005–2015. Annual daily OMEQe in mg per 1000 population, stratified by drug
Davies E et al. BJGP Open 2020; DOI: 10.3399/bjgpopen20X101122
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Strengths and limitations
Large sets of prescribing and diagnostic data have been validated as an accurate means for conducting 
healthcare population research,45,46 as they reduce recall bias and regional variation. In this study, 
anyone registered with included practices and prescribed an opioid medicine were included in the 
analysis, avoiding selection bias. This is the first study of Welsh data to utilise OMEQe to better 
understand the burden of opioid prescribing on the population. Using linkage systems within SAIL 
datasets, data from people with a recorded cancer diagnosis could be excluded from analysis. The 
data confidently reflects prescribing for non- cancer pain, unlike other recent studies that assumed 
the majority of prescribing was attributable to persisting, non- cancer pain based on longevity of 
prescribing and dose forms used.2,6
Other studies have suggested large increases in prescribing are attributable to a range of drugs.2,6,47 
The current study showed that three drugs were responsible for the majority of prescribing. This may, 
in part, be owing to the effective use of National Prescribing Indicators, which, in particular, have 
encouraged morphine to be used as first- line ‘strong’ opioid.48
Prescribing data provide an indication of intention to treat but does not confirm consumption. It 
also does not indicate the diagnosis or how long an individual might have been using the medication. 
Moreover, data presented here did not identify people receiving more than one opioid medicine and, 
so, would have higher individual OMEQe burdens.
Figure 3 Trends in opioid prescribing across Wales, 2005–2015. Annual daily OMQEe (mg) per 1000 population, stratified by deprivation. Welsh Index of 
Multiple Deprivation 2011 (WIMD 2011), where WIMD1 = most deprived, WIMD5 = least deprived.
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It was not possible to access dispensing data, which provides details required to accurately calculate 
OMEQ. The authors' estimated measure (OMEQe) required assumptions to be made in regard of daily 
dose prescribed. Also, quantity could not be verified in order to calculate duration of use. However, 
the trends are similar to those reported elsewhere in the UK.1–3,6,27,44
Further analysis is required to determine an individual’s daily intake, where multiple opioids and 
strengths of products are prescribed. While prescription numbers have started to stabilise or reduce 
since the end of the study,6,48,49 concerns remain about the number of people receiving supramaximal 
opioid doses and lengthy durations of use.11,32
In the study, opioid medicines were identified by Read codes and accuracy of data extraction 
depended on the inclusivity of the coding used. Similar rationales for deciding which opioid products 
to include in analysis of primary care prescribing have been adopted by other UK- based authors.1,3,6,27 
However, incomplete coding lists could result in an under- representation of prescribing.
Table 3 Trends in OMEQe (mg) prescribing stratified by deprivation
Oral or transdermal opioids
Deprivation quintile Total daily OMEQe dose (mg) 
prescribed
Total daily OMEQe dose (mg) 
per 1000 population
WIMD1
2005 10 319 636 21 757
2015 21 167 919 43 176
Rate change, % 105.1 98.4
Total prescribeda 176 824 265
WIMD2
2005 8 590 375 18 203
2015 17 399 026 35 475
Rate change, % 102.5 94.9
Total prescribeda 146 459 878
WIMD3
2005 7 684 060 17 108
2015 15 342 942 32 564
Rate change, % 99.7 90.3
Total prescribeda 129 880 669
WIMD4
2005 5 374 595 12 242
2015 10 878 897 23 534
Rate change, % 102.4 92.2
Total prescribeda 93 691 687
WIMD5
2005 4 486 035 9 381
2015 8 721 170 17 557
Rate change, % 94.4 87.2
Total prescribeda 76 112 569
aTotal prescribed 2005–2015. Annual OMEQe calculated as per method and stratified by 
deprivation quintile (Welsh Index of Multiple Deprivation [WIMD2011], where WIMD1 = 
most deprived, WIMD5 = least deprived). OMEQe = estimated oral morphine equivalent.
Davies E et al. BJGP Open 2020; DOI: 10.3399/bjgpopen20X101122
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Comparison with existing literature
Examining trends by prescription numbers alone is likely to underestimate the opioid burden within 
a population. Using English data, Curtis et al demonstrated a 34% growth in prescription numbers 
equated to a 127% increase in OMEQ burden between 1998 and 2016.6 In the present study, a 44% 
increase in prescription numbers in Wales, translated into a 95% increase in opioid burden using the 
OMEQe measure described.
Another measure of prescribing is defined daily doses (DDD), devised by the World Health 
Organization:50 DDDs are ‘the assumed average maintenance dose per day for a drug used for its 
main indication in adults.’ However, DDDs vary for each drug and between formulations of the same 
drug.50 When OMEQ was used to compare prescribing in four Nordic countries, it demonstrated 
noteworthy differences in patterns of opioid consumption compared with those seen with DDDs.43 
‘Weak’ opioids, such as codeine, carry higher DDD values than ‘strong’ opioids like morphine. 
Countries where codeine predominated, appeared to have high overall opioid prescribing, which was 
reversed when OMEQ was used and the contribution of ‘strong’ opioids accounted for.43
Prescribers’ understanding of OMEQ is poor.51–53 Use of OMEQ as a measure of prescribing might 
improve comprehension of opioid equivalence and lead to safer prescribing.
Substantial increases in opioid prescribing, with higher levels in more deprived populations, were 
also reported in other parts of the UK2,27 and internationally.54–57 Increased levels of prescribing in areas 
of high socioeconomic deprivation has been linked to greater reported pain intensity.26 However, 
limited evidence supports the notion that opioids are effective at reducing pain, particularly in the 
longer term.8,58,59 High- dose opioids (above 120 mg OMEQ) have been associated with increased 
levels of pain.60,61 In the context of this and previous studies,2,6,26,27 the implications of increased opioid 
prescribing in more deprived areas are concerning. It exposes the most vulnerable people to higher 
levels of medicines, which may be ineffective at best, and could cause additional health and well- 
being complications.11
Implications for practice
OMEQ is a useful measure of opioid utilisation in the general population and an individual basis.25 This 
study has demonstrated differences between assumed burden of opioid prescribing using OMEQe and 
prescriptions issued, which might have important clinical implications. Evaluating opioid prescribing 
using OMEQ would provide easily comparable data that better reflects clinical practice. Reasons 
for disparities in opioid burden between areas of deprivation need further investigation. Lack of 
availability and acceptability of non- pharmacological management and services have been suggested 
among reasons why prescribing is favoured.62,63 Use of OMEQ as a measure of opioid burden should 
be considered as a means of identifying ‘at risk’ populations and individuals, as prescription numbers 
reduce.
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